AQST
HealthcareAquestive Therapeutics, Inc.
$6.23
$-0.22 (-3.41%)
Jan 5, 2026
Price History (1Y)
Analysis
Aquestive Therapeutics, Inc. is a healthcare company that operates in the drug manufacturers - specialty & generic industry. With a market capitalization of $760.08 million, it has a relatively large scale compared to its peers. The company employs 142 individuals and operates within the sector of Healthcare. The company's financial health reveals significant challenges. Its operating margin stands at -89.6%, indicating substantial losses. Furthermore, its profit margin is -158.9%, highlighting severe profitability issues. Additionally, Aquestive Therapeutics reported a net income of -$68,979,000 and an EBITDA of -$55,203,000 in the most recent quarter. The company's cash balance stands at $129.06 million, while it has debt amounting to $41.38 million. Aquestive Therapeutics' valuation metrics paint a concerning picture. Its forward P/E ratio is -13.95, and its price to book ratio is -183.24. The company's revenue growth rate has been negative at -5.4% year-over-year, indicating a decline in sales performance. The dividend yield is not applicable as the company does not pay dividends.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; KYNMOBI a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
Visit website →Key Statistics
- Market Cap
- $760.08M
- P/E Ratio
- N/A
- 52-Week High
- $7.55
- 52-Week Low
- $2.12
- Avg Volume
- 2.80M
- Beta
- 1.66
Company Info
- Exchange
- NGM
- Country
- United States
- Employees
- 142